CN116440274A - c-MET及其激活剂的应用 - Google Patents
c-MET及其激活剂的应用 Download PDFInfo
- Publication number
- CN116440274A CN116440274A CN202310259609.XA CN202310259609A CN116440274A CN 116440274 A CN116440274 A CN 116440274A CN 202310259609 A CN202310259609 A CN 202310259609A CN 116440274 A CN116440274 A CN 116440274A
- Authority
- CN
- China
- Prior art keywords
- met
- cisplatin
- cells
- activator
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012190 activator Substances 0.000 title claims abstract description 26
- 229960004316 cisplatin Drugs 0.000 claims abstract description 36
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 36
- 210000002768 hair cell Anatomy 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 238000012216 screening Methods 0.000 claims abstract description 10
- 230000006378 damage Effects 0.000 claims abstract description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000000090 biomarker Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 48
- 230000004900 autophagic degradation Effects 0.000 abstract description 22
- 238000011282 treatment Methods 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 3
- 239000001963 growth medium Substances 0.000 description 17
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 15
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 15
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 7
- 210000003027 ear inner Anatomy 0.000 description 5
- JRWCBEOAFGHNNU-UHFFFAOYSA-N 6-[difluoro-[6-(1-methyl-4-pyrazolyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl]quinoline Chemical compound C1=NN(C)C=C1C1=NN2C(C(F)(F)C=3C=C4C=CC=NC4=CC=3)=NN=C2C=C1 JRWCBEOAFGHNNU-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 241000212749 Zesius chrysomallus Species 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101150105382 MET gene Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033109 Ototoxicity Diseases 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 2
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003030 auditory receptor cell Anatomy 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000003477 cochlea Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 231100000262 ototoxicity Toxicity 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 102000003954 Autophagy-Related Proteins Human genes 0.000 description 1
- 108010082399 Autophagy-Related Proteins Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 101150026630 FOXG1 gene Proteins 0.000 description 1
- 102100020871 Forkhead box protein G1 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229920009405 Polyvinylidenefluoride (PVDF) Film Polymers 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000004957 autophagosome Anatomy 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002266 hair cells auditory Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及c‑MET及其激活剂的应用，在用低剂量顺铂处理毛细胞时，加入c‑MET激活剂，细胞的增殖活性比仅用低剂量顺铂处理细胞组高，同时发现其过程伴随着自噬表达水平的升高；而抑制c‑MET的表达，毛细胞的生存活性降低，但自噬水平略微下降，本发明提出c‑MET可应用在筛选顺铂损伤的毛细胞的治疗靶点或药物中，c‑MET激活物可应用保护顺铂损伤的毛细胞的药物，为减轻顺铂所致毛细胞的损伤及筛选相关药物靶点提供研究方向。
Description
技术领域
本发明用于生物技术领域，更具体地，本发明涉及c-MET及其激活剂的应用。
背景技术
顺铂作为无机药物化学领域的代表性药物，自1978年被美国食品和药物管理局(FDA)批准使用以来，已被用于卵巢癌、睾丸癌、膀胱癌、肺癌等多种实体肿瘤的临床一线化疗，是临床应用最广泛的广谱抗癌药之一。其作用机制为：顺铂进入细胞被活化后，与细胞核内DNA结合，形成加合物，抑制DNA的转录和复制，从而诱导细胞凋亡。顺铂疗效显著，但其缺点也很明显，比如剂量限制性毒性(耳毒性、肾毒性、神经毒性、骨髓抑制等)，严重的胃肠道反应(恶心、呕吐等)。顺铂的耳毒性与内耳毛细胞的损伤有关，近年来，随着各种肿瘤的发病率的增高，顺铂的临床使用率逐渐增高，因顺铂的使用造成听力损伤的化疗病人的人数随之增加。目前，尚未有相关药物可减轻顺铂所致的听力损伤。
自噬是细胞在自噬基因的调控下，利用溶酶体降解自身细胞质蛋白或受损的细胞器的过程，同时实现细胞本身的代谢需要和某些细胞器的更新。根据相关文献报导（参见文献1和文献2）内耳毛细胞的自噬，在一定条件下可保护细胞，提高内耳细胞存活率。
细胞间质上皮转换因子（c-Met），也叫肝细胞生长因子受体（HGFR），是MET基因编码产生的具有自主磷酸化活性的跨膜受体，为受体酪氨酸激酶家族成员，c-Met激活的细胞内下游信号通路可促进细胞增殖和分化、细胞生存、DNA修复等。肝细胞生长因子 (HGF)，是目前研究的生物学活性最广泛的生长因子，HGF作用于受体c-Met，形成了HGF/c-Met信号转导系统，形成磷酸化的MET基因（p-MET），激活下游细胞内信号通路。据相关文献表明（参见文献3和文献4）HGF/c-Met信号通路存在于耳蜗中，参与血管纹的发育及新霉素导致的内耳毛细胞损伤过程。目前，c-Met对顺铂损伤的毛细胞的保护作用尚未研究，因此我们期望通过研究为减轻顺铂所致的听力损伤治疗及药物开发提供依据，降低顺铂在化疗过程中因耳毒性产生的副作用影响，为顺铂安全应用提供保证。
文献1：He ZH, Li M, Fang QJ, et al. FOXG1 promotes aging inner earhair cell survival through activation of the autophagypathway. Autophagy.2021;17(12):4341-4362.
文献2：He Z, Guo L, Shu Y, et al. Autophagy protects auditory haircells against neomycin-induced damage. Autophagy. 2017;13(11):1884-1904
文献3：Shibata S, Miwa T, Wu HH, Levitt P, Ohyama T. Hepatocyte GrowthFactor-c-MET SignalingMediates the Development of Nonsensory Structures ofthe Mammalian Cochlea and Hearing. J Neurosci. 2016;36(31):8200-8209.
文献4：Zhao Y, Liu P, Zhang N, et al. Targeting the cMETpathwayaugments radiation response without adverse effect on hearing in NF2schwannoma models. ProcNatl Acad Sci U S A. 2018;115(9):E2077-E2084。
发明内容
本发明的是针对现有技术的不足，提供一种c-MET及其激活物的应用。
为了解决上述技术问题， 本发明c-MET在筛选顺铂损伤的毛细胞的治疗靶点或药物中的应用。
本发明c-Met及其激活物作为潜在生物标志物在保护顺铂损伤的毛细胞治疗靶点和药物筛选靶点中的应用。
本发明c-MET激活物在制备保护顺铂损伤的毛细胞的药物中的应用。
上述应用中以c-MET激活剂作为活性成分之一或唯一活性成分用于制备保护顺铂所损伤的毛细胞的药物制剂。c-MET激活剂可选择肝细胞生长因子HGF。
本发明还提供一种保护顺铂损伤的毛细胞的药物，含有c-MET激活物或其类似物。
本发明的有益效果是：本发明将HEI-OC1细胞分别在含顺铂的培养基、含顺铂+c-Met激活剂培养基、含顺铂+c-Met抑制剂的培养基中进行培养后测定不同处理组的细胞活性、通过蛋白质印迹分析p-MET及LC3II/I的表达水平并对各处理组的自噬水平进行检测，证 明c-Met及其激活剂对通过增强自噬减轻顺铂所致毛细胞损伤，为c-Met及其激活剂在保护顺铂所损伤的毛细胞的药物及药物研发提供研究基础。
附图说明
图1为CCK-8检测不同处理组HEI-OC1细胞的生存活性。
图2为不同处理组中p-MET的表达水平。
图3为不同处理组中LC3II/I的表达水平。
图4为LC3双荧光慢病毒自噬流检测不同处理组中自噬情况。
具体实施方式
下面结合说明书附图和具体实施例对本发明作出进一步地详细阐述，所述实施例只用于解释本发明，并非用于限定本发明的范围。下述实施例中所使用的试 验方法如无特殊说明，均为常规方法；所使用的材料、试剂等，如无特殊说明，为可从商业途径得到的 试剂和材料。
HEI-OC1细胞系（小鼠耳蜗毛细胞系）由OriCell公司（中国广州）购得，LC3双荧光重组慢病毒载体从吉凯基因科学股份有限公司（中国上海）购买，重组慢病毒载体为该公司商业产品，细胞及病毒均由本实验室保存；DMEM培养基和胎牛血清（FBS）分别由以色列的Biological Industries和Viva Cell公司生产；PBS缓冲液从索莱宝公司（中国北京）购得；含EDTA的胰酶细胞消化液（0.25%，含酚红）和Puromycin Dihydrochloride由碧云天公司（中国上海）生产；CCK-8试剂由山东思科捷公司生产；顺铂由爱必信公司（中国上海）生产；c-MET激活剂HGF和抑制剂JNJ38877605分别由美国的PeproTech和Selleck公司生产，两种药物均可从商业途径获得；p-MET（Y1234/Y1235）抗体和LC3II/I抗体分别由美国的Bio-Techne和Cell Signaling公司合成。
实施例1
1.培养HEI-OC1细胞，并给予其不同的药物处理
将冻存的HEI-OC1细胞取出，在33℃的水浴锅中解冻，将含有细胞的冻存液转移至含有10%FBS高糖培养基的离心管中，吹打混匀， 1000rpm离心5分钟，吸除上层液体后加入适量培养基，将细胞重悬，把细胞悬液转移至6cm皿中，放于CO2浓度为10%、温度为33℃的细胞培养箱中培养。
待贴壁细胞面积到达60-80%时，吸除培养皿中的培养基，PBS冲洗残余培养基，加入1ml含EDTA的胰酶细胞消化液（0.25%，含酚红），将细胞消化，待全部细胞脱离皿底后加入2ml培养基中和胰酶消化作用，将细胞溶液置于离心管中，经过离心和重悬后，按照1：3的传代比例种于6cm皿中，待贴壁细胞面积再次达60-80%时，再次传代，经历3次传代后，细胞状态稳定。当细胞需再次传代时，按照1：3的传代比例种于6孔板中，细胞培养箱中培养12h待细胞贴壁。
将细胞分为4组，分别为：DMEM组、CIS组、CIS+HGF组、CIS+JNJ组。DMEM组仅加入培养基即可，CIS组加入顺铂浓度为8 ug/ml的培养基，CIS+HGF组加入顺铂浓度为8 ug/ml和HGF浓度为20 ng/ml的培养基，CIS+JNJ组加入顺铂浓度为8 ug/ml和JNJ-38877605浓度为20 ng/ml的培养基。
2.CCK-8试剂检测不同处理组的细胞活性
（1）实验方法
将细胞按照10000个/孔、100ul/孔的比例种于96孔板中，待12h后，加入含有不同药物的培养基（即上述的DMEM组、CIS组、CIS+HGF组、CIS+JNJ组），24h后将各组细胞培养皿中的培养基吸除，在避光的状态下，加入含有10%CCK-8溶液的培养基，将细胞置于培养箱中孵育1h后，酶标仪选择波长为450nM检测其吸光度。
（2）实验结果
与DMEM组相比，CIS组细胞的增值活性明显降低；CIS+HGF组细胞生存活性高于CIS组，而CIS+JNJ组细胞生存活性低于CIS组。
3.蛋白质印迹分析p-MET及LC3II/I的表达水平
（1）实验方法
在经药物刺激24h后提取各组蛋白 ,BCA法测量蛋白浓度，100℃5min变性后，将样品分别加入10%和12%的胶板中进行 SDS-PAGE电泳，转自聚偏氟乙烯(PVDF)膜(转膜条件为：250mA，120min)，5％BSA封闭2h ,TBS缓冲液-0 .1％Tween20洗膜(10min×3次)，以浓度1∶1 000的一抗4℃过夜封闭、TBS缓冲液-0 .1％Tween20洗膜(10min×3次)、1∶4000 二抗室温封闭1h ,TBS缓冲液-0 .1％Tween20洗膜(10min ×3次)后滴加ECL发光液在化学发光成像仪进行显影，ImageJ进行灰度分析。
（2）实验结果
蛋白质印迹分析显示p-MET的表达水平：CIS+HGF组>DMEM组>CIS组>CIS+JNJ组，LC3II/I的表达水平为：CIS+HGF组>CIS组>CIS+JNJ组>DMEM组。
小鼠耳蜗毛细胞系（HEI-OC1）是为数不多的用于研究目的的小鼠听觉细胞系之一，本实施例中在HEI-OC1细胞培养过程中采用不同的条件，分别设置对照组（DMEM组）、顺铂处理组（CIS组）、 顺铂+c-MET激活剂处理组（CIS+HGF组）和顺铂+c-MET抑制剂处理组（CIS+JNJ组），与对照组相比，顺铂处理组细胞的增值活性明显降低，CIS+HGF组细胞生存活性高于CIS组，而CIS+JNJ组细胞生存活性低于CIS组；蛋白质印迹分析显示p-MET的表达水平CIS+HGF组>DMEM组>CIS组>CIS+JNJ组。从而证明激活c-MET基因对顺铂损伤的毛细胞有保护作用。
自噬增强时，LC3I转变成LC3II的量增多，即LC3II/LC3I的比值变大。图2和图3中p-MET和LC3II/LC3I表达之所以出现不同的原因是，正常情况下自噬的发生水平低，甚至没有。但是，c-Met基因作为一种重要的基因，在维持细胞的其他功能方面发挥着重要作用，所以在正常未受刺激的细胞（DMEM组）也是高度表达的。除去DMEM组，p-MET和LC3II/LC3I表达是一致的。从而证明激活 c-MET基因对顺铂损伤的毛细胞有保护作用。
实施例二
LC3双荧光慢病毒自噬流检测不同处理组的自噬水平
（1）实验方法
通过预实验确定选用HitransG 病毒感染增强液，MOI值为50，可有较高的转染率。将慢病毒（即LC3双荧光重组慢病毒载体）稀释至培养基内用于感染HEI-OC1细胞，利用浓度为1ug/ml的Puromycin筛选稳定的感染株，经过稳定的传代培养后，将细胞分成DMEM组、CIS组、CIS+HGF组、CIS+JNJ组，并加入相应的药物处理细胞，DMEM组仅加入培养基即可，CIS组加入顺铂浓度为8 ug/ml的培养基，CIS+HGF组加入顺铂浓度为8 ug/ml和HGF浓度为20 ng/ml的培养基，CIS+JNJ组加入顺铂浓度为8 ug/ml和JNJ-38877605浓度为20 ng/ml的培养基，24小时后观察自噬相关水平。
（2）实验结果
在自噬后期自噬小体与溶酶体结合时，pH值会发生改变，当pH<5时，Sens-GFP荧光发生淬灭（绿斑点消失），只能检测到红斑点（Sens-RFP）荧光的聚集。参见图4，最终LC3双荧光慢病毒自噬流检测结果显示CIS+HGF组融合后的图像，红斑点的数量明显高于CIS组和CIS+JNJ组，而DMEM组红斑点的数量最少，证明CIS+HGF组自噬水平明显高于CIS组和CIS+JNJ组，而DMEM组自噬水平最低。由此可知，c-MET及其激活剂对顺铂损伤的毛细胞的保护作用是通过增强自噬来实现的。
本发明在用低剂量顺铂处理毛细胞时，加入c-MET激活剂HGF，细胞的增殖活性比仅用低剂量顺铂处理细胞组高。同时发现其过程伴随着自噬表达水平的升高；而采用c-ME抑制剂JNJ38877605抑制c-MET的表达，毛细胞的生存活性降低，但自噬水平变化不明显。因此我们认为激活c-MET可增强自噬可减轻顺铂所致毛细胞损伤，同时为减轻顺铂所致毛细胞的损伤及筛选相关药物靶点提供研究方向。
本发明证实了c-Met具有保护顺铂所损伤的毛细胞的作用，另一方面其激活物有助于保护顺铂所损伤的毛细胞。本发明为筛选顺铂损伤的毛细胞的治疗靶点或制备相关药物提供依据，主要体现在治疗或药物筛选过程对c-Met有激活作用的可能会有治疗作用，便于对治疗或药物进行快速筛选，降低筛选难度和成本。本发明为c-Met及其激活物作为潜在生物标志物在保护顺铂损伤的毛细胞治疗靶点和药物筛选靶点中的应用提供研究基础。
Claims (6)
1.c-MET在筛选顺铂损伤的毛细胞的治疗靶点或药物中的应用。
2.c-Met及其激活物作为潜在生物标志物在保护顺铂损伤的毛细胞治疗靶点和药物筛选靶点中的应用。
3.c-MET激活物在制备保护顺铂损伤的毛细胞的药物中的应用。
4.根据权利要求3所述的应用，其特征在于：c-MET激活剂作为活性成分之一或唯一活性成分用于制备保护顺铂所损伤的毛细胞的药物制剂。
5.根据权利要求4所述的应用，其特征在于：c-MET激活剂为肝细胞生长因子HGF。
6.一种保护顺铂损伤的毛细胞的药物，其特征在于：含有c-MET激活物或其类似物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310259609.XA CN116440274A (zh) | 2023-03-17 | 2023-03-17 | c-MET及其激活剂的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310259609.XA CN116440274A (zh) | 2023-03-17 | 2023-03-17 | c-MET及其激活剂的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116440274A true CN116440274A (zh) | 2023-07-18 |
Family
ID=87127954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310259609.XA Pending CN116440274A (zh) | 2023-03-17 | 2023-03-17 | c-MET及其激活剂的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116440274A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060233755A1 (en) * | 2002-10-02 | 2006-10-19 | Yasufumi Kaneda | Drug for auditory dysfunction |
| US20150337024A1 (en) * | 2014-05-23 | 2015-11-26 | Washington State University | Novel lead compound for otoprotection: targeting hgf signaling with dihexa |
| KR20200120057A (ko) * | 2019-04-11 | 2020-10-21 | 경북대학교 산학협력단 | 알파-리포익산(alpha-lipoic acid)을 유효성분으로 함유하는 시스플라틴에 의한 이독성 난청 치료용 약학적 조성물 |
| CN115463141A (zh) * | 2022-09-30 | 2022-12-13 | 齐鲁制药有限公司 | 神经节苷脂gm1在用于听力损伤的药物中的用途 |
-
2023
- 2023-03-17 CN CN202310259609.XA patent/CN116440274A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060233755A1 (en) * | 2002-10-02 | 2006-10-19 | Yasufumi Kaneda | Drug for auditory dysfunction |
| US20150337024A1 (en) * | 2014-05-23 | 2015-11-26 | Washington State University | Novel lead compound for otoprotection: targeting hgf signaling with dihexa |
| KR20200120057A (ko) * | 2019-04-11 | 2020-10-21 | 경북대학교 산학협력단 | 알파-리포익산(alpha-lipoic acid)을 유효성분으로 함유하는 시스플라틴에 의한 이독성 난청 치료용 약학적 조성물 |
| CN115463141A (zh) * | 2022-09-30 | 2022-12-13 | 齐鲁制药有限公司 | 神经节苷脂gm1在用于听力损伤的药物中的用途 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cheng et al. | Melatonin restricts the viability and angiogenesis of vascular endothelial cells by suppressing HIF-1α/ROS/VEGF | |
| Iurlaro et al. | Glucose deprivation induces ATF4-mediated apoptosis through TRAIL death receptors | |
| Li et al. | The SDF-1/CXCR4 axis induces epithelial–mesenchymal transition in hepatocellular carcinoma | |
| Hu et al. | Knockdown of SIRT1 suppresses bladder cancer cell proliferation and migration and induces cell cycle arrest and antioxidant response through FOXO3a‐mediated pathways | |
| Furukawa et al. | PTEN gene transfer suppresses the invasive potential of human malignant gliomas by regulating cell invasion-related molecules | |
| Ge et al. | CD38 affects the biological behavior and energy metabolism of nasopharyngeal carcinoma cells | |
| Lee et al. | Interleukin‐1β enhances cell migration through AP‐1 and NF‐κB pathway‐dependent FGF2 expression in human corneal endothelial cells | |
| Yin et al. | Arsenic-induced apoptosis in the p53-proficient and p53-deficient cells through differential modulation of NFkB pathway | |
| Ocasio et al. | GSK-3 modulates SHH-driven proliferation in postnatal cerebellar neurogenesis and medulloblastoma | |
| Yun et al. | Cripto enhances proliferation and survival of mesenchymal stem cells by up-regulating JAK2/STAT3 pathway in a GRP78-dependent manner | |
| Li et al. | TAT-Apoptin induces apoptosis in the human bladder cancer EJ cell line and regulates Bax, Bcl-2, caspase-3 and survivin expression | |
| Xu et al. | Metformin modulates T cell function and alleviates liver injury through bioenergetic regulation in viral hepatitis | |
| Ali et al. | Dorzolamide synergizes the antitumor activity of mitomycin C against Ehrlich’s carcinoma grown in mice: role of thioredoxin-interacting protein | |
| Lei et al. | HEV ORF3 downregulatesCD14 and CD64 to impair macrophages phagocytosis through inhibiting JAK/STAT pathway | |
| WO2022143010A1 (zh) | 一种吡哆醛在制备治疗卵巢癌的药物中的用途 | |
| Lu et al. | Tumour necrosis factor‐α promotes BMHSC differentiation by increasing P2X7 receptor in oestrogen‐deficient osteoporosis | |
| Wei et al. | IL‐38 attenuates myocardial ischemia–reperfusion injury by inhibiting macrophage inflammation | |
| CN116440274A (zh) | c-MET及其激活剂的应用 | |
| Liu et al. | Synergistic inhibitory effects on hepatocellular carcinoma with recombinant human adenovirus Aspp2 and oxaliplatin via p53-independent pathway in vitro and in vivo | |
| Wang et al. | Rg1 Protects Hematopoietic Stem Cells from LiCl‐Induced Oxidative Stress via Wnt Signaling Pathway | |
| Zhang et al. | Effects of silencing the DUSP1 gene using lentiviral vector-mediated siRNA on the release of proinflammatory cytokines through regulation of the MAPK signaling pathway in mice with acute pancreatitis | |
| Li et al. | miR-26a prevents neural stem cells from apoptosis via β-catenin signaling pathway in cardiac arrest-induced brain damage | |
| Yangngam et al. | Intracellular IL-33 attenuates extracellular IL-33-induced cholangiocarcinoma cell proliferation and invasion via NF-κB and GSK-3β pathways | |
| Zhang et al. | Cholesterol suppresses human iTreg differentiation and nTreg function through mitochondria-related mechanisms | |
| CN110777201B (zh) | 骨桥蛋白在缺氧缺血性脑损伤中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |